InvestorsHub Logo
Followers 32
Posts 10384
Boards Moderated 0
Alias Born 04/20/2016

Re: jimmy667 post# 4087

Friday, 05/03/2019 4:19:33 PM

Friday, May 03, 2019 4:19:33 PM

Post# of 5006
Correct, I bought Aeri after a failure it went from 32 to 8 in a day. Bought at 10 sold at 68. Last yr ESPR dropped in half, bought the day after drop and nearly doubled in 4 months. Same thing with Sarepta although was very risky.

This trial would have been a grand slam if patients that have not gotten any relief from previous treatments. I am not sure what kind of power this trial will hold. Elevate is a completely different trial as it is an adjunctive treatment. Abilfy had a peak of 10 million dollars is sales, that is the patient subset market AV-101 is going after.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VTGN News